|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
84.71 CHF |
+2.11% | -12.94% | -4.50% | |
April 10, 2025 at 01:49 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Novartis Plans to Spend $23 Billion to Build, Expand 10 US Facilities |
02:01pm |
MT |
|
Novartis Plans to Spend $23 Billion to Build, Expand 10 US Facilities, Reuters Reports |
01:49pm |
MT |
|
Novartis Plans $23 Billion Investment to Construct, Expand 10 US Sites, Reuters Says |
01:45pm |
MT |
|
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats |
01:35pm |
RE |
|
US tariffs’ bark is worse than their (potential) bite for pharmas |
12:04pm |
 |
|
NOVARTIS AG : UBS reaffirms its Neutral rating |
04:30am |
ZD |
|
European shares resume selloff as trade war escalates; healthcare slumps |
Apr. 09 |
RE |
|
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs — Update |
Apr. 09 |
DJ |
|
Trump says “It’s you next!” to pharmaceutical labs |
Apr. 09 |
 |
|
NOVARTIS AG : UBS reaffirms its Neutral rating |
Apr. 09 |
ZD |
|
Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines |
Apr. 09 |
DJ |
|
Global Bonds, Stocks Selloff Continues as Trade War Casts Gloom Over Global Economy |
Apr. 09 |
DJ |
|
European shares resume selloff as trade war escalates; healthcare slumps |
Apr. 09 |
RE |
|
Global pharma shares plunge as Trump doubles down on tariff threat |
Apr. 09 |
RE |
|
European pharma companies warn Trump’s tariffs could expedite shift to US |
Apr. 08 |
RE |
|
European pharma companies warn Trump’s tariffs could expedite shift to US |
Apr. 08 |
RE |
|
Rocket Pharmaceuticals, Inc Appoints Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer, Effective from April 7, 2025 |
Apr. 07 |
CI |
|
EU Commission head discusses response to tariffs with auto, steel and pharma leaders |
Apr. 07 |
RE |
|
NOVARTIS AG : Receives a Buy rating from Deutsche Bank |
Apr. 07 |
ZD |
|
EU Commission head discusses response to tariffs with auto, steel and pharma leaders |
Apr. 07 |
RE |
|
NOVARTIS AG : JP Morgan reaffirms its Neutral rating |
Apr. 07 |
ZD |
|
Kalaris Therapeutics, Inc. Appoints Leone Patterson to Its Board of Directors and as Chair of the Board?s Audit Committee |
Apr. 04 |
CI |
|
NOVARTIS AG : Deutsche Bank reaffirms its Buy rating |
Apr. 04 |
ZD |
|
Sector Update: Health Care Stocks Lean Lower Premarket Thursday |
Apr. 03 |
MT |
|
Tariff Onslaught Ignites Recession Panic |
Apr. 03 |
|
NOVN: Dynamic Chart
Novartis AG is one of the world’s leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows:
– oncology (29.3%);
– immunology (18.5%);
– cardiovascular, renal and metabolic diseases (17%);
– neuroscience (9.4%).
The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products.
At the end of 2024, Novartis AG had over 30 production sites worldwide.
Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).
More about the company
Buy
Last Close Price
98.63USD
Average target price
115.59USD
Spread / Average Target
+17.20%
Consensus
Quarterly revenue – Rate of surprise
}
